Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ATTO
Strong SellAttovia Therapeutics, Inc. · Healthcare · United States · $891M
7
StockRankGet insider-trade alerts
Q
29
V
23
M
25
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM |
|---|---|---|---|
| Revenue | 0 | 1.4M | 1.4M |
| EPS | -1.75 | -2.37 | -2.42 |
| Shares | — | — | — |
| Debt | 0 | 5.3M | 4.8M |
| Equity | -46.8M | -107.4M | — |
| Op CF | -35.0M | -59.2M | -63.2M |
| Inv CF | -39.8M | -73.5M | — |
| Fin CF | 82.7M | 142.0M | — |
Loading 1Y...
PRICE (1Y)-5.5%
Close
$20.70
RSI (14)
52.9
SCORE BREAKDOWN
Quality
29
ROIC
-43.4%19.0
ROE
—N/A
GP/Assets
-34.7%2.6
Op. Margin
-5260.0%3.5
FCF/Assets
-37.1%10.8
Piotroski
458.7
Int. Cover
—N/A
D/E Ratio
0.04x74.3
Current Ratio
13.94x91.5
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-3.2x25.0
P/FCF
—N/A
P/B
-0.7x25.0
P/S
659.8x3.0
Div Yield
—N/A
Momentum
25
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$891M
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATTO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATTO | Attovia Therapeutics, Inc.(you) | $891M | 7 | Strong Sell |
| OLMA | Olema Pharmaceuticals, Inc. | $899M | 5 | Strong Sell |
| ANNX | Annexon, Inc. | $942M | 10 | Strong Sell |
| OBX | Obsidian Therapeutics, Inc. | $1.0B | 5 | Strong Sell |
| SANA | Sana Biotechnology, Inc. | $1.2B | 8 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $698M | 9 | Strong Sell |
| PROK | ProKidney Corp. | $731M | 4 | Strong Sell |
| WVE | Wave Life Sciences, Inc. | $993M | 2 | Strong Sell |
| SGP | SpyGlass Pharma, Inc. | $884M | 15 | Strong Sell |
| ODTX | Odyssey Therapeutics, Inc. | $1.2B | 5 | Strong Sell |
Peer medians: ROE -25.6% · P/E 28.9x · Gross margin 58.7%